- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...
Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
Founding CEO of Allele Biotech and President of the Scintillon Institute, he is an RNA molecular biologist advancing mRNA-based reprogramming and iPSC engineering. He develops high-potency transient ...
Insilicotrials Technologies SpA has entered into a collaborative partnership with Axoltis Pharma SA in the field of central nervous system (CNS) diseases, with the aim of optimizing the clinical ...
The Qiang Laboratory concentrates on using human induced pluripotent stem cell (hiPSC) based technologies to establish in vitro (distinct phenotypical CNS neuronal cultures) and ex vivo (3d forebrain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results